LAVA Therapeutics (NASDAQ:LVTX) Short Interest Down 50.6% in March

LAVA Therapeutics (NASDAQ:LVTX) was the recipient of a large decrease in short interest during the month of March. As of March 15th, there was short interest totalling 191,500 shares, a decrease of 50.6% from the February 28th total of 387,300 shares. Based on an average daily volume of 417,100 shares, the days-to-cover ratio is presently 0.5 days. Currently, 1.5% of the shares of the company are short sold.

Analysts Set New Price Targets

LVTX has been the subject of several analyst reports. Leerink Partners restated a “market perform” rating and issued a $2.00 price objective (down from $11.00) on shares of LAVA Therapeutics in a research note on Thursday, December 12th. Citizens Jmp downgraded LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, December 11th. Leerink Partnrs downgraded LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, December 12th. HC Wainwright reissued a “neutral” rating and issued a $1.50 target price (down from $2.00) on shares of LAVA Therapeutics in a report on Thursday, February 27th. Finally, JMP Securities reaffirmed a “market perform” rating and set a $6.00 price target on shares of LAVA Therapeutics in a report on Wednesday, December 11th. Five equities research analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $3.17.

LAVA Therapeutics Trading Down 0.8 %

Shares of NASDAQ LVTX traded down $0.01 during trading hours on Friday, hitting $1.29. 43,333 shares of the company traded hands, compared to its average volume of 173,459. LAVA Therapeutics has a 12 month low of $0.85 and a 12 month high of $3.57. The stock has a market capitalization of $33.92 million, a price-to-earnings ratio of -1.25 and a beta of 0.48. The company’s 50 day moving average price is $1.12 and its 200 day moving average price is $1.37.

Hedge Funds Weigh In On LAVA Therapeutics

A number of large investors have recently bought and sold shares of the business. Sanofi purchased a new position in LAVA Therapeutics in the fourth quarter valued at about $1,825,000. BNP Paribas Financial Markets purchased a new position in shares of LAVA Therapeutics in the 4th quarter worth approximately $40,000. Finally, Virtu Financial LLC bought a new position in shares of LAVA Therapeutics during the 3rd quarter worth approximately $32,000.

About LAVA Therapeutics

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.